Anika Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $34.51 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-03
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $34.00, a 13.37% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $29.99, a 24.59% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $39.77, a 4.03% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $38.23.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $34.51, a 3.98% increase from fiscal 2024.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $33.19, a 9.29% decline from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $36.59, a 15.38% decline from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $43.24, a 3.42% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $34.51 10-K · filed 2026-03-03 | ||||
| 2025-06-30 | $34.43 10-Q · filed 2025-11-05 | $34.03 10-Q · filed 2025-07-30 | |||
| 2025-03-31 | $34.00 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | $33.19 10-K · filed 2025-03-17 | ||||
| 2024-09-30 | $37.50 10-Q · filed 2024-11-04 | ||||
| 2024-06-30 | $39.40 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $29.99 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $36.59 10-K · filed 2024-03-15 | ||||
| 2023-09-30 | $36.40 10-Q · filed 2023-11-03 | ||||
| 2023-06-30 | $36.61 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $39.77 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $43.24 10-K · filed 2023-03-16 | ||||
| 2022-09-30 | $44.08 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $44.25 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $38.23 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | $44.77 10-K · filed 2022-03-11 | ||||
| 2021-09-30 | $44.32 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |